ABVC BioPharma, Inc. (ABVC)

USD 0.49

(0.73%)

Market Cap (In USD)

6.29 Million

Revenue (In USD)

152.43 Thousand

Net Income (In USD)

-10.51 Million

Avg. Volume

73.13 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.405-2.45
PE
-
EPS
-
Beta Value
0.816
ISIN
US00091F3047
CUSIP
00091F106
CIK
1173313
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Uttam Yashwant Patil Ph.D.
Employee Count
-
Website
https://www.abvcpharma.com
Ipo Date
2004-11-10
Details
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.